Leriglitazone
Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases. Society and culture Legal status In January 2024, the European Medicines Agency The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products ... (EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L. In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone. Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy. References Thiazolidinediones Experimental drugs {{Pharma-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]